KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Inventory (2016 - 2025)

Historic Inventory for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $11.5 billion.

  • Pfizer's Inventory fell 215.85% to $11.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 billion, marking a year-over-year decrease of 215.85%. This contributed to the annual value of $10.9 billion for FY2024, which is 649.72% up from last year.
  • Pfizer's Inventory amounted to $11.5 billion in Q3 2025, which was down 215.85% from $11.7 billion recorded in Q2 2025.
  • In the past 5 years, Pfizer's Inventory registered a high of $11.7 billion during Q3 2024, and its lowest value of $8.5 billion during Q2 2021.
  • For the 5-year period, Pfizer's Inventory averaged around $10.2 billion, with its median value being $10.2 billion (2023).
  • In the last 5 years, Pfizer's Inventory tumbled by 704.68% in 2021 and then surged by 1749.68% in 2022.
  • Over the past 5 years, Pfizer's Inventory (Quarter) stood at $9.1 billion in 2021, then decreased by 0.86% to $9.0 billion in 2022, then grew by 13.45% to $10.2 billion in 2023, then rose by 6.5% to $10.9 billion in 2024, then rose by 5.69% to $11.5 billion in 2025.
  • Its last three reported values are $11.5 billion in Q3 2025, $11.7 billion for Q2 2025, and $10.9 billion during Q1 2025.